Cue Biopharma (CUE) Competitors $0.76 -0.02 (-2.18%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$0.74 -0.02 (-2.23%) As of 04/17/2025 04:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CUE vs. DBVT, NBTX, DMAC, CGC, FULC, DERM, ACRS, IPHA, MOLN, and PBYIShould you be buying Cue Biopharma stock or one of its competitors? The main competitors of Cue Biopharma include DBV Technologies (DBVT), Nanobiotix (NBTX), DiaMedica Therapeutics (DMAC), Canopy Growth (CGC), Fulcrum Therapeutics (FULC), Journey Medical (DERM), Aclaris Therapeutics (ACRS), Innate Pharma (IPHA), Molecular Partners (MOLN), and Puma Biotechnology (PBYI). These companies are all part of the "pharmaceutical products" industry. Cue Biopharma vs. DBV Technologies Nanobiotix DiaMedica Therapeutics Canopy Growth Fulcrum Therapeutics Journey Medical Aclaris Therapeutics Innate Pharma Molecular Partners Puma Biotechnology Cue Biopharma (NASDAQ:CUE) and DBV Technologies (NASDAQ:DBVT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, community ranking, profitability, media sentiment, risk and valuation. Which has preferable valuation & earnings, CUE or DBVT? Cue Biopharma has higher earnings, but lower revenue than DBV Technologies. DBV Technologies is trading at a lower price-to-earnings ratio than Cue Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCue Biopharma$9.29M5.07-$50.73M-$0.75-1.02DBV Technologies$15.73M10.44-$72.73M-$5.00-1.60 Is CUE or DBVT more profitable? Cue Biopharma has a net margin of -468.02% compared to DBV Technologies' net margin of -815.73%. DBV Technologies' return on equity of -106.07% beat Cue Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Cue Biopharma-468.02% -156.38% -88.07% DBV Technologies -815.73%-106.07%-76.17% Does the MarketBeat Community prefer CUE or DBVT? DBV Technologies received 259 more outperform votes than Cue Biopharma when rated by MarketBeat users. Likewise, 54.22% of users gave DBV Technologies an outperform vote while only 52.33% of users gave Cue Biopharma an outperform vote. CompanyUnderperformOutperformCue BiopharmaOutperform Votes14652.33% Underperform Votes13347.67% DBV TechnologiesOutperform Votes40554.22% Underperform Votes34245.78% Which has more volatility and risk, CUE or DBVT? Cue Biopharma has a beta of 2.02, suggesting that its share price is 102% more volatile than the S&P 500. Comparatively, DBV Technologies has a beta of -0.08, suggesting that its share price is 108% less volatile than the S&P 500. Does the media favor CUE or DBVT? In the previous week, Cue Biopharma had 5 more articles in the media than DBV Technologies. MarketBeat recorded 11 mentions for Cue Biopharma and 6 mentions for DBV Technologies. Cue Biopharma's average media sentiment score of 0.19 beat DBV Technologies' score of -0.23 indicating that Cue Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cue Biopharma 1 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral DBV Technologies 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals believe in CUE or DBVT? 35.0% of Cue Biopharma shares are held by institutional investors. Comparatively, 71.7% of DBV Technologies shares are held by institutional investors. 12.3% of Cue Biopharma shares are held by company insiders. Comparatively, 1.9% of DBV Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts prefer CUE or DBVT? Cue Biopharma currently has a consensus price target of $3.00, indicating a potential upside of 293.70%. DBV Technologies has a consensus price target of $22.50, indicating a potential upside of 181.95%. Given Cue Biopharma's higher possible upside, equities analysts plainly believe Cue Biopharma is more favorable than DBV Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cue Biopharma 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00DBV Technologies 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryCue Biopharma beats DBV Technologies on 10 of the 17 factors compared between the two stocks. Get Cue Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CUE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CUE vs. The Competition Export to ExcelMetricCue BiopharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$47.11M$6.45B$5.30B$7.34BDividend YieldN/A3.23%5.12%4.30%P/E Ratio-0.856.8921.8017.77Price / Sales5.07231.02379.9097.68Price / CashN/A65.6738.2634.64Price / Book0.935.916.443.98Net Income-$50.73M$142.72M$3.21B$247.52M7 Day Performance-0.54%4.35%2.84%1.82%1 Month Performance-21.04%-12.79%-8.65%-6.98%1 Year Performance-51.77%-9.70%11.38%1.49% Cue Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CUECue Biopharma4.3227 of 5 stars$0.76-2.2%$3.00+293.7%-53.3%$47.11M$9.29M-0.8560Gap DownDBVTDBV Technologies2.6359 of 5 stars$7.44+14.5%$22.50+202.4%+17.4%$153.03M$15.73M-1.6580Earnings ReportAnalyst ForecastShort Interest ↑NBTXNanobiotix1.8236 of 5 stars$3.17-3.1%$8.00+152.4%-37.9%$149.41M$36.22M0.00100Gap DownDMACDiaMedica Therapeutics1.1009 of 5 stars$3.48-0.6%$8.00+129.9%+36.2%$149.14MN/A-6.2120Short Interest ↑News CoverageGap DownCGCCanopy Growth2.1442 of 5 stars$0.93+1.1%$2.00+114.9%-81.7%$147.59M$276.75M-0.243,150Options VolumeNews CoverageFULCFulcrum Therapeutics2.0157 of 5 stars$2.72+8.4%$8.63+217.1%-54.0%$146.82M$80M-8.77100Short Interest ↓News CoveragePositive NewsGap UpDERMJourney Medical2.2147 of 5 stars$6.96-3.2%$9.88+41.9%+61.9%$145.39M$56.13M-7.4090Short Interest ↑Positive NewsGap UpHigh Trading VolumeACRSAclaris Therapeutics1.8451 of 5 stars$1.33-5.0%$11.67+777.2%-7.3%$143.53M$18.72M-2.56100Positive NewsGap UpIPHAInnate Pharma1.9875 of 5 stars$1.71-6.6%$11.50+572.5%-17.9%$143.35M$12.63M0.00220Gap DownMOLNMolecular Partners1.6254 of 5 stars$3.54-0.8%$12.00+239.0%+1.5%$142.93M$4.97M-1.65180PBYIPuma Biotechnology3.3417 of 5 stars$2.83-2.4%$7.00+147.3%-44.7%$140.40M$230.47M5.90200Analyst Upgrade Related Companies and Tools Related Companies DBV Technologies Alternatives Nanobiotix Alternatives DiaMedica Therapeutics Alternatives Canopy Growth Alternatives Fulcrum Therapeutics Alternatives Journey Medical Alternatives Aclaris Therapeutics Alternatives Innate Pharma Alternatives Molecular Partners Alternatives Puma Biotechnology Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CUE) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | Sponsored100-year-old investment secret predicts what?!A 100-year-old indicator has quietly predicted nearly every major market meltdown — including the Dot-Com Bust...Weiss Ratings | SponsoredThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredTrump 2028 could be a “bonanza” for investorsAs you may have heard, Donald Trump is planning to run for a THIRD term in 2028. Recently he told NBC news ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cue Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cue Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CUE Stock Free CUE Stock Alerts